Helen K. Angell

Medicine · Health Sciences

27h-index15.5kcitations126works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(71), Cancer-related molecular mechanisms research(22), Immune Cell Function and Interaction(21), Ferroptosis and cancer prognosis(20), RNA modifications and cancer(20)

Publications124 total

Supplementary Figure 2 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Figure 3 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Table 1 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Figure 4 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Data from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Figure 1 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Figure 4 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Table 1 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Figure 5 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Table 2 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Figure 6 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
Cancer Research Communications·2025Open Access
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer
Molecular Cancer·2025· 2 citedOpen Access
Supplementary Figure S1 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S11 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
Figure 1 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Material S1 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S2 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S7 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Figure S2 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
2025Open Access
page 1 of 7Next →

Frequent Co-authors

Jérôme Galon(18), Gabriela Bindea(11), Bernhard Mlecnik(11), Franck Pagès(9), Anne Berger(8), Susan M. Domchek(8), Pia Herbolsheimer(8), Tessa Fredriksen(7), J. Carl Barrett(7), Sophie Postel‐Vinay(6), Christopher Gresty(6), Felicia Ng(6), Amos Kirilovsky(5), Maximilian J. Waldner(5), Lucie Lafontaine(5), Viia Valge-Archer(5), Matthew Krebs(5), Mark C. Lanasa(5), Emma V. Jones(5), Bella Kaufman(5)